Cargando…

Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations

Although it has always been believed that radiation has immunosuppressive effects, more and more preclinical and clinical trials have shown that the combination of radiotherapy and immunotherapy has a potential synergistic effect to treat cancers including urological malignancies. When radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Haoran, Shi, Ming, Xu, Hang, Bai, Shengjiang, Xiong, Xingyu, Wei, Qiang, Yang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917304/
https://www.ncbi.nlm.nih.gov/pubmed/33658847
http://dx.doi.org/10.2147/CMAR.S288337
_version_ 1783657670437240832
author Lei, Haoran
Shi, Ming
Xu, Hang
Bai, Shengjiang
Xiong, Xingyu
Wei, Qiang
Yang, Lu
author_facet Lei, Haoran
Shi, Ming
Xu, Hang
Bai, Shengjiang
Xiong, Xingyu
Wei, Qiang
Yang, Lu
author_sort Lei, Haoran
collection PubMed
description Although it has always been believed that radiation has immunosuppressive effects, more and more preclinical and clinical trials have shown that the combination of radiotherapy and immunotherapy has a potential synergistic effect to treat cancers including urological malignancies. When radiotherapy is combined with immunotherapy, improved prognosis has been observed in different urinary tumors. However, there is no standard treatment, such as the optimal dose/fractionation and the sequence of immunotherapy and radiotherapy. In this review, we discussed the effects of radiotherapy on the cancer immune system and emphasized the synergy of radiotherapy combined with immunotherapy. Although it has significantly improved the prognosis of tumors, there are still some unresolved questions about how to best use this combination in clinical practice. Ongoing trials will provide further information on the interaction of radiotherapy combined with immunotherapy, and are expected to guide clinical practice and improve clinical outcomes.
format Online
Article
Text
id pubmed-7917304
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79173042021-03-02 Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations Lei, Haoran Shi, Ming Xu, Hang Bai, Shengjiang Xiong, Xingyu Wei, Qiang Yang, Lu Cancer Manag Res Review Although it has always been believed that radiation has immunosuppressive effects, more and more preclinical and clinical trials have shown that the combination of radiotherapy and immunotherapy has a potential synergistic effect to treat cancers including urological malignancies. When radiotherapy is combined with immunotherapy, improved prognosis has been observed in different urinary tumors. However, there is no standard treatment, such as the optimal dose/fractionation and the sequence of immunotherapy and radiotherapy. In this review, we discussed the effects of radiotherapy on the cancer immune system and emphasized the synergy of radiotherapy combined with immunotherapy. Although it has significantly improved the prognosis of tumors, there are still some unresolved questions about how to best use this combination in clinical practice. Ongoing trials will provide further information on the interaction of radiotherapy combined with immunotherapy, and are expected to guide clinical practice and improve clinical outcomes. Dove 2021-02-24 /pmc/articles/PMC7917304/ /pubmed/33658847 http://dx.doi.org/10.2147/CMAR.S288337 Text en © 2021 Lei et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Lei, Haoran
Shi, Ming
Xu, Hang
Bai, Shengjiang
Xiong, Xingyu
Wei, Qiang
Yang, Lu
Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
title Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
title_full Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
title_fullStr Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
title_full_unstemmed Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
title_short Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
title_sort combined treatment of radiotherapy and immunotherapy for urological malignancies: current evidence and clinical considerations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917304/
https://www.ncbi.nlm.nih.gov/pubmed/33658847
http://dx.doi.org/10.2147/CMAR.S288337
work_keys_str_mv AT leihaoran combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations
AT shiming combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations
AT xuhang combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations
AT baishengjiang combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations
AT xiongxingyu combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations
AT weiqiang combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations
AT yanglu combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations